Celularity (CELU) Preferred Stock Liabilities (2019 - 2021)
Celularity (CELU) posted quarterly Preferred Stock Liabilities of $75.0 million for Q2 2021, little changed year-over-year from $75.0 million in Q2 2020, and little changed quarter-over-quarter from $75.0 million in Q1 2021.
Celularity (CELU) Preferred Stock Liabilities (2019 - 2021) Analysis & Trends
Celularity (CELU) has reported Preferred Stock Liabilities for 3 consecutive years, with $75.0 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Preferred Stock Liabilities changed 0.0% year-over-year to $75.0 million; the TTM figure through Jun 2021 stood at $75.0 million (changed 0.0% YoY), while the FY2020 annual figure was $75.0 million, down 63.6% from the prior year.
- Preferred Stock Liabilities held at $75.0 million in Q2 2021 per CELU's latest filing, from $75.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $290.6 million in Q1 2020 and bottomed at $75.0 million in Q2 2020.
- Historically, Preferred Stock Liabilities has averaged $155.3 million across 3 years, with a median of $75.0 million in 2020.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 0.0% in 2021 and fell as far as 74.19% in 2021.
- Celularity's Preferred Stock Liabilities stood at $206.0 million in 2019, then plunged by 63.6% to $75.0 million in 2020, then changed by 0.0% to $75.0 million in 2021.
- Business Quant data shows CELU's Preferred Stock Liabilities at $75.0 million in Q2 2021, $75.0 million in Q1 2021, and $75.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Celularity | 20.99 Mn | 14.82 Mn | -3.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 75.00 Mn |
| Mar 31, 2021 | 75.00 Mn |
| Dec 31, 2020 | 75.00 Mn |
| Sep 30, 2020 | 290.62 Mn |
| Jun 30, 2020 | 75.00 Mn |
| Mar 31, 2020 | 290.62 Mn |
| Dec 31, 2019 | 206.04 Mn |